Literature DB >> 11550311

A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution.

E C Wooten1, D Fults, R Duggirala, K Williams, A P Kyritsis, M L Bondy, V A Levin, P O'Connell.   

Abstract

Cancers that arise from astrocytes in the adult CNS present as either anaplastic astrocytomas (AAs) or as more aggressive glioblastomas multiforme (GBMs). GBMs either form de novo or progress from AAs. We proposed to examine the molecular genetic relationship between these CNS tumors by conducting a genome-wide allelic imbalance analysis that included 70 loci on examples of AA and GBM. We found significant loss of heterozygosity (LOH) at 13 discrete chromosomal loci in both AAs and GBMs. Loss was significant in both AAs and GBMs at 9 of these loci. AAs show the highest rates of LOH at chromosomes 1p, 4q, 6p, 9p, 11p, 11q, 13q, 14q, 15p, 17p, 17q, and 19q. GBMs showed the greatest losses at 1p, 6q, 8p, 9p, 10p, 10q, 11p, 13q, 17p, 17q, 18p, 18q, and 19q. GBMs also demonstrated significant amplification at the epidermal growth factor receptor locus (7p12). These data suggest that there are three classes of loci involved in glioma evolution. First are loci that are likely involved in early events in the evolution of both AAs and GBMs. The second class consists of AA-specific loci, typified by higher LOH frequency than observed in GBMs (4q, 6p, 17p, 17q, 19q). The third class consists of GBM-specific loci (6q, 8p, 10, 18q). Damage at these loci may either lead to de novo GBMs or permit existing AAs to progress to GBMs. Glioma-related LOH profiles may have prognostic implications that could lead to better diagnosis and treatment of brain cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11550311      PMCID: PMC1920743          DOI: 10.1093/neuonc/1.3.169

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  12 in total

1.  An astroblastoma case associated with loss of heterozygosity on chromosome 9p.

Authors:  Nobuhiro Hata; Tadahisa Shono; Koji Yoshimoto; Masahiro Mizoguchi; Tadao Kawamura; Shinji Nagata; Kenichi Matsumoto; Kenshi Hayashi; Toru Iwaki; Tomio Sasaki
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

2.  Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Authors:  J C Easaw; W P Mason; J Perry; N Laperrière; D D Eisenstat; R Del Maestro; K Bélanger; D Fulton; D Macdonald
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

Review 3.  Current progress for the use of miRNAs in glioblastoma treatment.

Authors:  Amanda Tivnan; Kerrie Leanne McDonald
Journal:  Mol Neurobiol       Date:  2013-04-28       Impact factor: 5.590

4.  Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification.

Authors:  Barbara Klink; Ben Schlingelhof; Martin Klink; Karen Stout-Weider; Stephan Patt; Evelin Schrock
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

Review 5.  Some speculation on the origin of glioblastoma.

Authors:  Matthew R Quigley; Christopher Post; Garth Ehrlich
Journal:  Neurosurg Rev       Date:  2006-11-23       Impact factor: 3.042

6.  High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas.

Authors:  Kasumi Araki; Kazuhiko Nozaki; Tetsuya Ueba; Masaaki Tatsuka; Nobuo Hashimoto
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Authors:  Ayman I Omar; Warren P Mason
Journal:  Core Evid       Date:  2010-06-15

8.  Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.

Authors:  Yasufumi Goto; Kazuo Koyanagi; Norihiko Narita; Yutaka Kawakami; Minoru Takata; Aya Uchiyama; Linhda Nguyen; Tung Nguyen; Xing Ye; Donald L Morton; Dave S B Hoon
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

9.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Authors:  Okezie O Kanu; Betsy Hughes; Chunhui Di; Ningjing Lin; Jinrong Fu; Darell D Bigner; Hai Yan; Cory Adamson
Journal:  Clin Med Oncol       Date:  2009-04-08

10.  Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study.

Authors:  M Wager; P Menei; J Guilhot; P Levillain; S Michalak; B Bataille; J-L Blanc; F Lapierre; P Rigoard; S Milin; F Duthe; D Bonneau; C-J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.